Launch YC: ParcelBio: Programmable delivery of mRNA medicines
Summary
We will initially use this technology to develop drugs for long-overlooked kidney disorders, chronic liver diseases, and immune system dysregulationbut thats just the beginning.The Problem: mRNA therapeutics have already saved millions of lives with the advent of the COVID-19 vaccine. The current delivery vehicle of choice is a lipid nanoparticle (LNP), which is essentially a fat droplet that encapsulates the mRNA. LNPs work great for vaccines, but applications beyond vaccines require more specific targeting and higher doses than what best-in-class LNP technologies can provide.Our Solution: Our proprietary technology, which we call STAmP (Stabilization and Targeting by Annealing mRNA to ParcelOligos), is a completely new way of delivering an mRNA medicine without a nanoparticle. STAmPs key innovation is the use of ParcelOligos, which was inspired by the clinical success of another type of RNA therapeutic called siRNA that has already moved on from nanoparticle-based delivery. These keys are based on naturally occurring molecules that the body already uses to recognize specific cell types.We will use STAmP to develop wholly-owned drugs for kidney, liver, and immune system disorders.